Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Status:
Completed
Trial end date:
2017-12-18
Target enrollment:
Participant gender:
Summary
This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib
compared with single-agent treatment, as selected by the investigator from the offered
options of pralatrexate or gemcitabine or romidepsin, in participants with relapsed or
refractory peripheral T-cell lymphoma (PTCL). Note: romidepsin was not used as a single-agent
comparator outside the United States of America (USA) as supply was not available.